Deborah S Mortensen

List of Publications by Year
in descending order

15	899	759233 12	996975 15
papers	citations	h-index	g-index

17	17	17	1236
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and Biological Evaluation of a Novel Series of Furans:Â Ligands Selective for Estrogen Receptor Î±. Journal of Medicinal Chemistry, 2001, 44, 3838-3848.	6.4	246
2	Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chemistry and Biology, 1999, 6, 205-219.	6.0	209
3	A phase I doseâ€escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CCâ€223 in patients with advanced solid tumors or multiple myeloma. Cancer, 2015, 121, 3481-3490.	4.1	68
4	Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. Journal of Medicinal Chemistry, 2015, 58, 5599-5608.	6.4	60
5	CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro. Oncotarget, 2017, 8, 74688-74702.	1.8	50
6	Furans with basic side chains: synthesis and biological evaluation of a novel series of antagonists with selectivity for the estrogen receptor alpha. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2521-2524.	2.2	48
7	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Molecular Cancer Therapeutics, 2015, 14, 1295-1305.	4.1	48
8	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. Clinical Cancer Research, 2013, 19, 5722-5732.	7.0	46
9	Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6793-6799.	2.2	31
10	Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223. Journal of Medicinal Chemistry, 2015, 58, 5323-5333.	6.4	29
11	Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1588-1591.	2.2	26
12	Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001. Journal of Medicinal Chemistry, 2021, 64, 18193-18208.	6.4	21
13	Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0025321.	3.2	8
14	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. Molecular Cancer Therapeutics, 2014, 13, 504-516.	4.1	7
15	Discovery of the Selective Protein Kinase C-Î¸ Kinase Inhibitor, CC-90005. Journal of Medicinal Chemistry, 2021, 64, 11886-11903.	6.4	2